Abstract
The overexpression or abnormal activation of cyclo‑oxygenase‑2 (COX‑2) has been reported in pancreatic cancer cells. NS‑398, a selective inhibitor of COX‑2, is unable to inhibit pancreatic cancer cell proliferation, as determined by a Cell Counting Kit 8 assay. However, it does increase cancer cell invasiveness, and therefore the invasiveness of the PANC‑1 cells was determined, along with the activation of P38, which was assessed by western blotting. In the present study, to evaluate the mechanisms underlying the action of NS‑398 in pancreatic cancer cells, PANC‑1 cells were treated with NS‑398, and the invasion signaling pathways of cluster of differentiation (CD)147‑matrix metalloproteinase (MMP)‑2 and mitogen‑activated protein kinases were evaluated. The results showed that NS‑398‑induced the expression of CD147 and MMP‑2 via the activation of P38, which was involved in antiproliferative activity and induced pancreatic cancer cell invasiveness. The PANC‑1 cells were also co‑treated with CD147 small interfering (si)RNA and NS‑398, and it was found that the NS‑398‑induced activation of P38 was not inhibited by CD147 siRNA, however, the expression of MMP‑2 was inhibited. CD147 siRNA inhibited the invasiveness of the pancreatic ...Continue Reading
References
Jan 25, 1991·Cell·L A LiottaW G Stetler-Stevenson
Nov 1, 1989·Cytometry·I J Fidler
Feb 5, 2000·Carcinogenesis·M T Yip-SchneiderC J Sweeney
Oct 6, 2001·Stroke; a Journal of Cerebral Circulation·E ArakiC Iadecola
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Douglas J E ElderChristos Paraskeva
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Takuro KanekuraTamotsu Kanzaki
Sep 3, 2003·Nature Reviews. Drug Discovery·Sanjay KumarJohn C Lee
Oct 24, 2003·Molecular Pharmacology·Robert RamerBurkhard Hinz
Dec 13, 2003·Clinical & Experimental Metastasis·Jiro OkamiMorito Monden
Mar 16, 2005·DNA and Cell Biology·Soichiro HonjoHisao Ito
Mar 23, 2005·Biochimie·Eric E GabisonSuzanne Menashi
May 26, 2005·Pharmacological Reviews·Vincenzo MollaceDaniela Salvemini
Aug 9, 2005·Molecular Cancer·Seiya YoshidaThomas E Adrian
Feb 16, 2006·Immunology·Vyacheslav YurchenkoMichael Bukrinsky
Jun 17, 2006·Molecular Cancer Research : MCR·Yi TangLi Yan
Jun 24, 2006·Pathology International·Kazuki NabeshimaMasahiro Kikuchi
Dec 6, 2006·Cancer Research·Xiang ChenJing Chang
Sep 20, 2007·Cell Proliferation·N BanuM Pignatelli
Jun 24, 2008·Rheumatology·Y YangP Zhu
Feb 17, 2009·Proteome Science·Naomi WalshPaul Dowling
Mar 30, 2010·Clinical and Experimental Immunology·V YurchenkoM Bukrinsky
Oct 26, 2010·European Journal of Pharmacology·Mahmoud YounsJörg D Hoheisel
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Dec 2, 2011·Histochemistry and Cell Biology·Marta WójcikFrank C Schultze
Dec 16, 2011·Investigational New Drugs·Kaouther Kolli-BouhafsPhilippe Rondé
Aug 18, 2012·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Joelle HillionLinda M S Resar
Aug 28, 2012·Oncology Reports·Da-Peng DuanWu-Lin You
Feb 22, 2013·Oncology Letters·Shino Shibata-KobayashiKeiichi Nakagawa
Feb 28, 2013·BMC Cancer·Alastair L YoungMark A Hull
Mar 5, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Xinyan WangMin Wang
Jun 19, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Wen Feng YanGang Wu
Jun 19, 2013·Molecular Carcinogenesis·Carina PereiraMário Dinis-Ribeiro
Citations
Nov 28, 2019·Journal of Cellular Physiology·Fuzhou LiJixiang Niu
Aug 25, 2016·Oncotarget·Juan SuXiang Chen
Nov 16, 2016·Oncotarget·Feng WeiYan Liu
Sep 21, 2017·Oncology Letters·Yuhei HorikawaYasutomo Nasu
Jun 26, 2021·Journal of Cellular and Molecular Medicine·Ping WangJunhong Dong